Results 21 to 30 of about 159,806 (339)

Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tumors

open access: yesGut and Liver, 2018
Background/AimsCurrent guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding.Methods : Gastric ESD cases with ...
Sooyeon Oh   +10 more
doaj   +1 more source

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial [PDF]

open access: yes, 2019
Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy.
Abano, Nenette   +966 more
core   +5 more sources

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]

open access: yes, 2019
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Al-Shahi Salman, Rustam   +16 more
core   +1 more source

Antiplatelet therapy in cardiovascular disease: Current status and future directions

open access: yesBritish Journal of Clinical Pharmacology, 2022
Antiplatelet medications remain a cornerstone of therapy for atherosclerotic cardiovascular and cerebrovascular diseases. In primary prevention (patients with cardiovascular risk factors but no documented events, symptoms or angiographic disease), there ...
G. Passacquale   +3 more
semanticscholar   +1 more source

NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN

open access: yesРоссийский кардиологический журнал, 2015
Antithrombotic treatment of acute coronary syndrome leads to much better outcomes of the disease. The article focuses on the arguments and evidence for the addition to antiplatelet drugs the rivaroxaban 2,5 mg two times per day for secondary prevention ...
I. N. Bokarev, A. V. Golub
doaj   +1 more source

9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a potentially novel antiplatelet drug which antagonizes the effect of thromboxane A2 [PDF]

open access: yes, 2018
Background: Currently, used oral antiplatelet drugs are both limited and associated with the risk of treatment failure/resistance. Research in this area is hence highly desired.
Applová, Lenka   +8 more
core   +1 more source

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]

open access: yes, 2014
ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou   +10 more
core   +1 more source

Precision antiplatelet therapy

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2023
A State of the Art lecture titled "Personalizing Antiplatelet Therapy Based on Platelet Turnover and Metabolic Phenotype" was presented by Bianca Rocca at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2022. Increased variability in drug response may be associated with serious, mechanism-based and off-target side effects ...
Rocca, Bianca, Patrono, Carlo
openaire   +2 more sources

Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation

open access: yesAntioxidants, 2023
The thrombosis-related diseases are one of the leading causes of illness and death in the general population, and despite significant improvements in long-term survival due to remarkable advances in pharmacologic therapy, they continue to pose a ...
Luigi Falco   +7 more
doaj   +1 more source

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction : role of vorapaxar [PDF]

open access: yes, 2015
© 2015 Farag et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) LicenseAcute myocardial infarction (AMI) is generally attributed to coronary atherothrombotic ...
Farag, Mohamed   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy